Literature DB >> 35422504

Resistance is futile with fourth-generation EGFR inhibitors.

Michelangelo Marasco1, Sandra Misale2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35422504     DOI： 10.1038/s43018-022-00365-2

Source DB:  PubMed          Journal:  Nat Cancer        ISSN： 2662-1347


× No keyword cloud information.
  2 in total

1.  EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

Authors:  Anita Midha; Simon Dearden; Rose McCormack
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166
  2 in total
  2 in total

1.  Circumventing the roadblocks to targeting EGFR-driven cancers.

Authors: 
Journal:  Nat Cancer       Date:  2022-04

Review 2.  Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations.

Authors:  Jun Wang; Daniel Lam; Jeffrey Yang; Longqin Hu
Journal:  Med Chem Res       Date:  2022-09-01       Impact factor: 2.351
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.